| Primary | Troponin I (TnI) Area Under the Curve (AUC) | | | Posted | | Median | Inter-Quartile Range | ng*hr/mL | | pre-CABG surgery (after 5 to 7 days of assigned treatment, predischarge or 5 days post-CABG surgery (Approximately 12 days) | | | | ID | Title | Description |
|---|
| OG000 | Saxagliptin | Treatments to be administered are saxagliptin 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery. | | OG001 | Placebo | Treatments to be administered are placebo 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery. |
| | | Title | Denominators | Categories |
|---|
| | | Title | Measurements |
|---|
| - OG000463.25(228.74 to 928.29)
- OG001235.98(230.03 to 266.01)
|
|
| |
| Secondary | High Sensitive Troponin-I (hsTnT) Area Under the Curve | | | Posted | | Median | Inter-Quartile Range | ng*hr/mL | | pre-CABG surgery (after 5 to 7 days of assigned treatment, predischarge or 5 days post-CABG surgery (Approximately 12 days) | | | | ID | Title | Description |
|---|
| OG000 | Saxagliptin | Treatments to be administered are saxagliptin 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery. | | OG001 | Placebo | Treatments to be administered are placebo 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery. |
| |
| Secondary | Creatine Kinase-Myocardial Bands (CK-MB) Area Under the Curve | | | Posted | | Median | Inter-Quartile Range | ng*hr/mL | | pre-CABG surgery (after 5 to 7 days of assigned treatment, predischarge or 5 days post-CABG surgery (Approximately 12 days) | | | | ID | Title | Description |
|---|
| OG000 | Saxagliptin | Treatments to be administered are saxagliptin 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery. | | OG001 | Placebo | Treatments to be administered are placebo 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery. |
| |
| Secondary | Number of Major Adverse Cardiac Events (MACE) | Death, myocardial infarction (MI), or New congestive heart failure (CHF) | | Posted | | Number | | Cardiac Events | | Baseline to end of study (Approximately 35-37 days) | | | | ID | Title | Description |
|---|
| OG000 | Saxagliptin | Treatments to be administered are saxagliptin 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery. | | OG001 | Placebo | Treatments to be administered are placebo 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery. |
| |
| Secondary | Duration of Inotropic Support | | | Posted | | Mean | Standard Deviation | hours | | CABG surg until hosp discharge (Approximately 5 days) | | | | ID | Title | Description |
|---|
| OG000 | Saxagliptin | Treatments to be administered are saxagliptin 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery. | | OG001 | Placebo | Treatments to be administered are placebo 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery. |
| |
| Secondary | Number of Participants Who Had an Episode of Hypoglycemia | | | Posted | | Number | | participants | | baseline to end of study (Approximately 35-37 days) | | | | ID | Title | Description |
|---|
| OG000 | Saxagliptin | Treatments to be administered are saxagliptin 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery. | | OG001 | Placebo | Treatments to be administered are placebo 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery. |
| |
| Secondary | Number of Participants Who Required Intraaortic Balloon Pump (IABP) Support | | | Posted | | Number | | participants | | CABG to hospital discharge (Approximately 5 days) | | | | ID | Title | Description |
|---|
| OG000 | Saxagliptin | Treatments to be administered are saxagliptin 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery.daily | | OG001 | Placebo | Treatments to be administered are placebo 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery. |
| |
| Secondary | Need for Antiarrhythmic Therapy | | | Posted | | Number | | participants | | CABG surg to hospital discharge Approximately 5 days | | | | ID | Title | Description |
|---|
| OG000 | Saxagliptin | Treatments to be administered are saxagliptin 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery. | | OG001 | Placebo | Treatments to be administered are placebo 5 mg (once daily) to begin at randomization 5 to 7 days before CABG surgery, continuing through the peri-CABG surgery period and discharge, and for a total of 30 (± 5) days post-CABG surgery. |
| |